EUCTR2010-019033-98-DE进行中（未招募）不适用
A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma - i i i Study
niversity Clinical Center of Tuebingen0 个研究点开始时间: 2011年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Willing and able to give written informed consent;
- •Histological diagnosis of malignant melanoma;
- •Stage IV melanoma;
- •At least one injectable lesions > 5 mm (longest diameter) or at least 5 injectable lesions < 5 mm.
- •Measurable disease. Note: lesions, which are designated for direct IL -2 injections, must not be considered in the evaluation of measurability;
- •Men and women, ? 18 years of age;
- •Patient must have demonstrated 1 of the following in response to at least 1 cycle of 1 or more systemic regimens:
- •1) relapse following an objective response (PR/CR);
- •2) failed to demonstrate an objective response (PR/CR); or
- •3) inability to tolerate treatment due to unacceptable toxicity
- •At least 4 weeks since treatment (chemotherapy, biochemotherapy, surgery, radiation, immunotherapy, etc.) for melanoma and recovered from any clinically significant toxicity experienced during treatment;
- •Life expectancy =3 months;
- •ECOG performance status of 0 or 1;
- •Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of ipilimumab;
- •No known active or chronic infection with HIV, Hepatitis B, or Hepatitis C;
- •Required values for initial laboratory tests:
- •1.WBC ? 2000/µL
- •2.ANC ? 1000/µL
- •3.Platelets ? 75000/µL
- •4.Hemoglobin ? 9 g/dL (? 8 g/dL; may be transfused)
- •5.Creatinine? 2.0 x ULN
- •6.AST/ALT ? 2.5 x ULN (? 5 times x ULN for patients with liver metastases)
- •7.Bilirubin ? 2.0 x ULN, (except patients with Gilbert’s Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
- •Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study and for up to 26 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Any other prior malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix;
- •Ocular melanoma; mucosal melanoma
- •Either untreated or symptomatic central nervous system (CNS) metastases (patients with brain metastases who are identified at screening may be rescreened after the lesion(s) have been appropriately treated);
- •Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study, as are patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener’s Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). Patients with vitiligo may be included.
- •Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.
- •Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab).
- •A history of prior systemic treatment with ipilimumab, CD137 agonist, CTLA 4 inhibitor, CTLA-4 agonist or IL-2 in stage IV melanoma.
- •Concomitant or less than 4 weeks off therapy with any of the following: interferon; other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; chronic use of systemic corticosteroids.
- •Women of childbearing potential (WOCBP), defined in Section 5.3, who:
- •1.are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 26 weeks after cessation of study drug, or
- •2.have a positive pregnancy test at baseline, or
- •3.are pregnant or breastfeeding.
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious) illness.
研究者
相似试验
已完成
2 期
A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancernon-squamous non-small-cell lung cancerJPRN-UMIN000009476The Tokyo cooperative oncology group39
进行中（未招募）
1 期
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patientsAdvanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïveCohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenanceMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003083-98-HUEllipses Pharma Limited384
进行中（未招募）
1 期
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patientsEUCTR2020-003083-98-GBEllipses Pharma Limited384
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancer.MedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006289Term: Benign and malignant breast neoplasmsSystem Organ Class: 100000004872MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2021-005238-40-ITEQRx International, Inc.100
进行中（未招募）
不适用
Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in patients with relapsed or refractory inflammatory breast cancer - Lapatinib in relapsed or refractory inflammatory breast cancer (IBC)Relapsed or refractory infammatory breast cancer (IBC)EUCTR2004-001906-29-BEGlaxoSmithKline R&D Ltd60